Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

Vermeire, Severine; Noman, Maja; Van Assche, Gert; Baert, Filip; D'Haens, Geert; Rutgeerts, Paul
September 2007
Gut;Sep2007, Vol. 56 Issue 9, p1226
Academic Journal
Background: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation. Aims and methods: To investigate which of the IS—that is, methotrexate (MTX) or azathioprine (AZA)—is most effective at reducing the risk of ATI formation, a multicentre cohort of 174 patients with Crohn's disease, treated with IFX in an on-demand schedule, was prospectively studied. Three groups were studied: no IS (n = 59), concomitant MTX (n = 50) and concomitant AZA (n = 65). ATI and IFX concentrations were measured in a blinded manner at Prometheus Laboratories before and 4 weeks after each infusion. Results: ATIs were detected in 55% (96/174) of the patients. The concomitant use of IS therapy (AZA or MTX) was associated with a lower incidence of ATIs (53/115; 46%) compared with patients not taking concomitant IS therapy (43/59; 73%; p<0.001). The incidence of ATIs was not different for the MTX group (44%) compared with the AZA group (48%). Patients not taking IS therapy had lower IFX levels (median 2.42 μg/ml (interquartile range (IQR) 1–10.8), maximum 21 μg/ml) 4 weeks after any follow-up infusion than patients taking concomitant IS therapy (median 6.45 μg/ml (IQR 3–11.6), maximum 21 μg/ml; p = 0.065), but there was no difference between MTX or AZA. In patients who developed significant ATIs >8 pg/ml during follow-up, the IFX levels 4 weeks after the first infusion were retrospectively found to be significantly lower than in patients who did not develop ATIs on follow-up or had inconclusive ATIs. Conclusion: Concomitant IS therapy reduces ATI formation associated with IFX treatment and improves the pharmacokinetics of IFX. There is no difference between MTX and AZA in reducing these risks. ATI profoundly influences the pharmacokinetics of IFX. The formation of ATIs >8 μg/ml is associated with lower serum levels of IFX already at 4 weeks after its first administration.


Related Articles

  • Crohn's disease: current treatment options. Akobeng, A. K. // Archives of Disease in Childhood;Sep2008, Vol. 93 Issue 9, p787 

    There is no known cure for Crohn's disease (CD), but a better understanding of the evidence base of both established treatments (such as enteral nutrition, corticosteroids, 5-aminosalicylates and immunosuppressive agents) and emerging treatments (such as the anti-tumour necrosis factor-α...

  • An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease. Sandborn, William J.; Hanauer, Stephen; Loftus, Edward V.; Tremaine, William J.; Kane, Sunanda; Cohen, Russell; Hanson, Karen; Johnson, Therese; Schmitt, Debra; Jeche, Resa // American Journal of Gastroenterology;Oct2004, Vol. 99 Issue 10, p1984 

    BACKGROUND: We assessed the tolerability and clinical benefit of adalimumab, a human antibody to tumor necrosis factor (TNF), in patients with Crohn's disease who had previously received and responded to the chimeric anti-TNF antibody infliximab, but who no longer had a sustained response and/or...

  • Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial. Steenholdt, Casper; Bendtzen, Klaus; Brynskov, Jørn; Thomsen, emptyv; Ainsworth, Mark A // American Journal of Gastroenterology;Jul2014, Vol. 109 Issue 7, p1055 

    OBJECTIVES:Cost-effective guidance of therapeutic strategy in Crohn's disease patients with secondary infliximab (IFX) treatment failure may be achieved by serum IFX and anti-IFX antibody (Ab) measurements by radioimmunoassay (RIA). This study investigated implications of using other techniques...

  • The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Casteele, Niels Vande; Khanna, Reena; Levesque, Barrett G.; Stitt, Larry; Zou, G. Y.; Singh, Sharat; Lockton, Steve; Hauenstein, Scott; Ohrmund, Linda; Greenberg, Gordon R.; Rutgeerts, Paul J.; Gils, Ann; Sandborn, William J.; Vermeire, Séverine; Feagan, Brian G. // Gut;Oct2015, Vol. 64 Issue 10, p1539 

    Objective: Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an...

  • NICE recommends treatments for Crohn's disease.  // Practice Nurse;5/28/2010, Vol. 39 Issue 10, p6 

    The article presents the recommendation by the British National Institute for Health and Clinical Excellence (NICE) of infliximab and adalimumab as treatments for patients with Crohn's disease.

  • Infliximab.  // Reactions Weekly;9/4/2010, Issue 1317, p28 

    The article describes the case of a 53-year-old man who had pityriasis lichenoides chronica while taking infliximab, and became well through methotrexate.

  • Benefit of intravenous immunoglobulin in a patient with longstanding polymyositis/systemic sclerosis overlap syndrome. Abelha-Aleixo, J.; Bernardo, A.; Costa, L. // Acta Reumatológica Portuguesa;abr-jun2015, Vol. 40 Issue 2, p176 

    The authors describe the case of a 49-year-old female with a progressive tetraparesis with two years of evolution, whose diagnostic study revealed a polymyositis/systemic sclerosis overlap syndrome. The patient was completely dependent and bedridden and had pulmonary, gastrointestinal, skin and...

  • Infliximab.  // Reactions Weekly;7/22/2006, Issue 1111, p14 

    The article presents a case study of a 40-year-old woman who was diagnosed with reactivation histoplasmosis while being treated with infliximab for Crohn's disease.

  • Infliximab.  // Reactions Weekly;5/13/2006, Issue 1101, p11 

    The article presents a case study of a 22-year-old woman who developed interstitial pneumonia on being treated with infliximab for fistulating Crohn's disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics